Declared Dividend • 21h
Dividend increased to CN¥0.13 Dividend of CN¥0.13 is 25% higher than last year. Ex-date: 11th June 2026 Payment date: 11th June 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (39% earnings payout ratio) and cash flows (26% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 103% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥14.57, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 20x in the Chemicals industry in China. Total loss to shareholders of 6.0% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.27 per share. Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.10 (vs CN¥0.09 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.10 (up from CN¥0.09 in 1Q 2025). Revenue: CN¥1.02b (up 18% from 1Q 2025). Net income: CN¥87.8m (up 10.0% from 1Q 2025). Profit margin: 8.7% (down from 9.3% in 1Q 2025). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Tillkännagivande • Apr 25
Valiant Co.,Ltd, Annual General Meeting, May 21, 2026 Valiant Co.,Ltd, Annual General Meeting, May 21, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Yantai, Shandong China Tillkännagivande • Mar 31
Valiant Co.,Ltd to Report Q1, 2026 Results on Apr 25, 2026 Valiant Co.,Ltd announced that they will report Q1, 2026 results on Apr 25, 2026 Price Target Changed • Feb 03
Price target increased by 16% to CN¥18.67 Up from CN¥16.10, the current price target is an average from 3 analysts. New target price is 12% above last closing price of CN¥16.73. Stock is up 65% over the past year. The company is forecast to post earnings per share of CN¥0.45 for next year compared to CN¥0.26 last year. Tillkännagivande • Dec 31
Valiant Co.,Ltd to Report Fiscal Year 2025 Results on Apr 25, 2026 Valiant Co.,Ltd announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.099 (up from CN¥0.089 in 3Q 2024). Revenue: CN¥956.4m (up 19% from 3Q 2024). Net income: CN¥87.5m (up 8.4% from 3Q 2024). Profit margin: 9.1% (in line with 3Q 2024). Revenue missed analyst estimates by 9.9%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Tillkännagivande • Sep 30
Valiant Co.,Ltd to Report Q3, 2025 Results on Oct 27, 2025 Valiant Co.,Ltd announced that they will report Q3, 2025 results on Oct 27, 2025 Reported Earnings • Aug 24
Second quarter 2025 earnings: EPS exceeds analyst expectations Second quarter 2025 results: EPS: CN¥0.14 (up from CN¥0.12 in 2Q 2024). Revenue: CN¥1.01b (down 1.0% from 2Q 2024). Net income: CN¥138.3m (up 18% from 2Q 2024). Profit margin: 14% (up from 12% in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 53%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Major Estimate Revision • Aug 23
Consensus EPS estimates increase by 17% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from CN¥0.454 to CN¥0.532. Revenue forecast steady at CN¥4.16b. Net income forecast to grow 134% next year vs 48% growth forecast for Chemicals industry in China. Consensus price target up from CN¥14.17 to CN¥15.60. Share price rose 7.4% to CN¥13.99 over the past week. Price Target Changed • Aug 22
Price target increased by 7.4% to CN¥14.77 Up from CN¥13.75, the current price target is an average from 3 analysts. New target price is 5.6% above last closing price of CN¥13.99. Stock is up 71% over the past year. The company is forecast to post earnings per share of CN¥0.62 for next year compared to CN¥0.26 last year. Tillkännagivande • Jul 02
Valiant Co.,Ltd to Report First Half, 2025 Results on Aug 22, 2025 Valiant Co.,Ltd announced that they will report first half, 2025 results on Aug 22, 2025 Declared Dividend • Jun 01
Dividend reduced to CN¥0.10 Dividend of CN¥0.10 is 67% lower than last year. Ex-date: 6th June 2025 Payment date: 6th June 2025 Dividend yield will be 0.9%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (42% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 139% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Major Estimate Revision • May 01
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥4.73b to CN¥4.19b. EPS estimate fell from CN¥0.669 to CN¥0.528 per share. Net income forecast to grow 138% next year vs 49% growth forecast for Chemicals industry in China. Consensus price target up from CN¥13.75 to CN¥14.13. Share price was steady at CN¥10.92 over the past week. Board Change • Apr 30
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chairman of the Supervisory Board Lei Zhang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 27
Valiant Co.,Ltd (SZSE:002643) announces an Equity Buyback for CNY 200 million worth of its shares. Valiant Co.,Ltd (SZSE:002643) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of class A common shares. The shares will be repurchased at a purchase price of CNY 16.55 per share. The purpose of the program is to reduce the company's registered capital. The program will be valid for 12 months. Reported Earnings • Apr 25
First quarter 2025 earnings released: EPS: CN¥0.09 (vs CN¥0.11 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.09 (down from CN¥0.11 in 1Q 2024). Revenue: CN¥861.2m (down 8.2% from 1Q 2024). Net income: CN¥79.9m (down 19% from 1Q 2024). Profit margin: 9.3% (down from 11% in 1Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Tillkännagivande • Apr 25
Valiant Co.,Ltd, Annual General Meeting, May 21, 2025 Valiant Co.,Ltd, Annual General Meeting, May 21, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Yantai, Shandong China Buy Or Sell Opportunity • Apr 04
Now 21% undervalued Over the last 90 days, the stock has risen 3.7% to CN¥10.99. The fair value is estimated to be CN¥13.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.7% over the last 3 years. Earnings per share has declined by 6.5%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 49% in the next 2 years. Tillkännagivande • Mar 31
Valiant Co.,Ltd to Report Q1, 2025 Results on Apr 25, 2025 Valiant Co.,Ltd announced that they will report Q1, 2025 results on Apr 25, 2025 Buy Or Sell Opportunity • Feb 13
Now 20% undervalued The stock has been flat over the last 90 days, currently trading at CN¥10.79. The fair value is estimated to be CN¥13.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.7% over the last 3 years. Earnings per share has declined by 6.5%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 49% in the next 2 years. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥10.60, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Chemicals industry in China. Total loss to shareholders of 48% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥14.59 per share. Buy Or Sell Opportunity • Jan 02
Now 24% undervalued Over the last 90 days, the stock has risen 9.0% to CN¥11.30. The fair value is estimated to be CN¥14.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.7% over the last 3 years. Earnings per share has declined by 6.5%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 49% in the next 2 years. Tillkännagivande • Dec 31
Valiant Co.,Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Valiant Co.,Ltd announced that they will report fiscal year 2024 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥12.42, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Chemicals industry in China. Total loss to shareholders of 44% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥14.52 per share. Major Estimate Revision • Nov 23
Consensus EPS estimates increase by 26% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥3.70b to CN¥3.81b. EPS estimate increased from CN¥0.45 to CN¥0.566 per share. Net income forecast to grow 21% next year vs 53% growth forecast for Chemicals industry in China. Consensus price target of CN¥12.75 unchanged from last update. Share price fell 2.7% to CN¥10.51 over the past week. Buy Or Sell Opportunity • Nov 13
Now 20% undervalued Over the last 90 days, the stock has risen 28% to CN¥11.55. The fair value is estimated to be CN¥14.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.7% over the last 3 years. Earnings per share has declined by 6.5%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. Reported Earnings • Oct 30
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥0.089 (down from CN¥0.20 in 3Q 2023). Revenue: CN¥806.3m (down 27% from 3Q 2023). Net income: CN¥80.7m (down 57% from 3Q 2023). Profit margin: 10.0% (down from 17% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 50%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Buy Or Sell Opportunity • Oct 11
Now 20% undervalued Over the last 90 days, the stock has risen 2.1% to CN¥9.77. The fair value is estimated to be CN¥12.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 51% in the next 2 years. Tillkännagivande • Sep 30
Valiant Co.,Ltd to Report Q3, 2024 Results on Oct 30, 2024 Valiant Co.,Ltd announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥9.43, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.08 per share. Major Estimate Revision • Aug 29
Consensus revenue estimates fall by 15% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥4.86b to CN¥4.15b. EPS estimate fell from CN¥0.908 to CN¥0.561 per share. Net income forecast to grow 21% next year vs 45% growth forecast for Chemicals industry in China. Consensus price target down from CN¥18.25 to CN¥13.75. Share price rose 4.4% to CN¥8.35 over the past week. Price Target Changed • Aug 27
Price target decreased by 9.2% to CN¥16.63 Down from CN¥18.31, the current price target is an average from 4 analysts. New target price is 107% above last closing price of CN¥8.03. Stock is down 54% over the past year. The company is forecast to post earnings per share of CN¥0.90 for next year compared to CN¥0.84 last year. Reported Earnings • Aug 22
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.24 in 2Q 2023). Revenue: CN¥1.02b (down 2.2% from 2Q 2023). Net income: CN¥116.9m (down 45% from 2Q 2023). Profit margin: 12% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 26%. Earnings per share (EPS) also missed analyst estimates by 46%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Tillkännagivande • Jun 29
Valiant Co.,Ltd to Report First Half, 2024 Results on Aug 22, 2024 Valiant Co.,Ltd announced that they will report first half, 2024 results on Aug 22, 2024 Declared Dividend • Jun 01
Dividend of CN¥0.30 announced Shareholders will receive a dividend of CN¥0.30. Ex-date: 6th June 2024 Payment date: 6th June 2024 Dividend yield will be 2.6%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 61% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • May 31
Valiant Co.,Ltd Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 06 June 2024 Valiant Co.,Ltd announced 2023 final profit distribution plan to be implemented (A shares) of Cash dividend/10 shares (tax included) is CNY 3.00000000, Record date is 05 June 2024, Ex-date: 06 June 2024, Payment date is 06 June 2024. Major Estimate Revision • May 23
Consensus EPS estimates increase by 14% The consensus outlook for fiscal year 2024 has been updated. 2024 consensus EPS increased from CN¥0.831 to CN¥0.947. Revenues were reaffirmed at CN¥4.86b. Net income forecast to grow 36% next year vs 52% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥18.25. Share price was steady at CN¥11.44 over the past week. Major Estimate Revision • Apr 26
Consensus revenue estimates fall by 13% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥5.58b to CN¥4.86b. EPS estimate fell from CN¥1.04 to CN¥0.831 per share. Net income forecast to grow 21% next year vs 39% growth forecast for Chemicals industry in China. Consensus price target down from CN¥20.64 to CN¥18.31. Share price fell 8.4% to CN¥11.31 over the past week. Price Target Changed • Apr 22
Price target decreased by 7.3% to CN¥19.14 Down from CN¥20.64, the current price target is an average from 4 analysts. New target price is 72% above last closing price of CN¥11.12. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥0.98 for next year compared to CN¥0.84 last year. Tillkännagivande • Apr 21
Valiant Co.,Ltd, Annual General Meeting, May 16, 2024 Valiant Co.,Ltd, Annual General Meeting, May 16, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Yantai, Shandong China Reported Earnings • Apr 20
First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.11 (down from CN¥0.19 in 1Q 2023). Revenue: CN¥937.9m (down 9.2% from 1Q 2023). Net income: CN¥98.3m (down 44% from 1Q 2023). Profit margin: 11% (down from 17% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 08
Price target decreased by 12% to CN¥20.64 Down from CN¥23.54, the current price target is an average from 4 analysts. New target price is 58% above last closing price of CN¥13.02. Stock is down 26% over the past year. The company is forecast to post earnings per share of CN¥0.85 for next year compared to CN¥0.79 last year. Tillkännagivande • Mar 30
Valiant Co.,Ltd to Report Q1, 2024 Results on Apr 20, 2024 Valiant Co.,Ltd announced that they will report Q1, 2024 results on Apr 20, 2024 Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥11.78, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Chemicals industry in China. Total loss to shareholders of 40% over the past three years. Tillkännagivande • Dec 30
Valiant Co.,Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024 Valiant Co.,Ltd announced that they will report fiscal year 2023 results on Apr 20, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings: EPS exceeds analyst expectations Third quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥1.10b (down 12% from 3Q 2022). Net income: CN¥186.1m (up 22% from 3Q 2022). Profit margin: 17% (up from 12% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.5%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Major Estimate Revision • Oct 30
Consensus revenue estimates decrease by 11% The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CN¥4.91b to CN¥4.37b. EPS estimate unchanged at CN¥0.881 per share. Net income forecast to grow 47% next year vs 60% growth forecast for Chemicals industry in China. Consensus price target of CN¥23.26 unchanged from last update. Share price rose 8.8% to CN¥16.97 over the past week. Tillkännagivande • Oct 19
Valiant Co.,Ltd Announces Board Appointments Valiant Co.,Ltd held its 2nd Extraordinary General Meeting of 2023 on 17 October 2023, approved the appointment of Zhu Caifei and Zhang Yun as non-independent directors. Reported Earnings • Aug 19
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: EPS: CN¥0.24 (down from CN¥0.29 in 2Q 2022). Revenue: CN¥1.04b (down 14% from 2Q 2022). Net income: CN¥212.8m (down 18% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 6.7%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Jul 27
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. 2 highly experienced directors. Member of Supervisory Board Zhenjian Gu is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Jul 23
Valiant Co.,Ltd Approves Board Elections Valiant Co.,Ltd at its Extraordinary General Meeting held on 20 July 2023 approved the election of Tang Meng, Yang Yaowu and Yang Xiaoyue as non-independent directors. Buying Opportunity • Jul 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 3.5%. The fair value is estimated to be CN¥21.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 30% in 2 years. Earnings is forecast to grow by 63% in the next 2 years. Tillkännagivande • Jul 01
Valiant Co.,Ltd to Report First Half, 2023 Results on Aug 19, 2023 Valiant Co.,Ltd announced that they will report first half, 2023 results on Aug 19, 2023 Buying Opportunity • Jun 09
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 9.4%. The fair value is estimated to be CN¥20.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 30% in 2 years. Earnings is forecast to grow by 63% in the next 2 years. Tillkännagivande • Jun 03
Valiant Co.,Ltd Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 09 June 2023 Valiant Co.,Ltd announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 2.95000000 for the year 2022, payable on 09 June 2023. Record date is 08 June 2023. Ex-date is 09 June 2023. Buying Opportunity • May 16
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be CN¥20.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 30% in 2 years. Earnings is forecast to grow by 64% in the next 2 years. Reported Earnings • Apr 24
First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.25 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.19 (down from CN¥0.25 in 1Q 2022). Revenue: CN¥1.03b (down 25% from 1Q 2022). Net income: CN¥176.6m (down 24% from 1Q 2022). Profit margin: 17% (in line with 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Apr 21
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥5.80b to CN¥5.14b. EPS estimate fell from CN¥1.10 to CN¥0.923 per share. Net income forecast to grow 9.3% next year vs 38% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥22.59. Share price was steady at CN¥17.53 over the past week. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥18.82, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 32% over the past three years. Tillkännagivande • Dec 01
Valiant Co.,Ltd Approves Election of Lv Shaoyang as Director Valiant Co.,Ltd announced at the EGM held on November 29, 2022 that the company approved Election of Lv Shaoyang as a director. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. 3 highly experienced directors. Member of Supervisory Board Tianxiao Hu is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Price Target Changed • Nov 03
Price target decreased to CN¥23.80 Down from CN¥27.68, the current price target is an average from 2 analysts. New target price is 63% above last closing price of CN¥14.63. Stock is down 30% over the past year. The company is forecast to post earnings per share of CN¥0.93 for next year compared to CN¥0.69 last year. Reported Earnings • Oct 28
Third quarter 2022 earnings: EPS exceeds analyst expectations Third quarter 2022 results: EPS: CN¥0.17 (down from CN¥0.21 in 3Q 2021). Revenue: CN¥1.26b (down 11% from 3Q 2021). Net income: CN¥153.0m (down 20% from 3Q 2021). Profit margin: 12% (down from 14% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 21
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: EPS: CN¥0.29 (up from CN¥0.19 in 2Q 2021). Revenue: CN¥1.22b (up 19% from 2Q 2021). Net income: CN¥258.1m (up 53% from 2Q 2021). Profit margin: 21% (up from 17% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 17%. Over the next year, revenue is forecast to grow 14%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year. Tillkännagivande • May 31
Valiant Co.,Ltd Announces Cash Dividend, Payable on 06 June 2022 Valiant Co.,Ltd announced 2021 final profit distribution plan to be implemented (A shares) as Cash dividend/10 shares (tax included): CNY 2.55000000. Record date as 02 June 2022, ex-date as 06 June 2022 and payment date as 06 June 2022. Board Change • May 29
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Ying Guo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • May 04
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥17.85, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 80% over the past three years. Reported Earnings • Apr 28
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥0.25 (up from CN¥0.14 in 1Q 2021). Revenue: CN¥1.37b (up 74% from 1Q 2021). Net income: CN¥232.8m (up 77% from 1Q 2021). Profit margin: 17% (in line with 1Q 2021). Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 9.4%. Over the next year, revenue is forecast to grow 16%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 14% per year. Board Change • Apr 27
High number of new directors There are 8 new directors who have joined the board in the last 3 years. Director Wei Li was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 28
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: CN¥0.69 (up from CN¥0.56 in FY 2020). Revenue: CN¥4.36b (up 49% from FY 2020). Net income: CN¥626.7m (up 24% from FY 2020). Profit margin: 14% (down from 17% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 7.9%. Over the next year, revenue is forecast to grow 26%, compared to a 47% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 14% per year. Buying Opportunity • Feb 11
Now 22% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be CN¥26.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% per annum over the last 3 years. Earnings per share has grown by 11% per annum over the last 3 years. Buying Opportunity • Jan 25
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 1.2%. The fair value is estimated to be CN¥26.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% per annum over the last 3 years. Earnings per share has grown by 11% per annum over the last 3 years. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥24.21, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 171% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.00 per share. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.15 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥1.42b (up 101% from 3Q 2020). Net income: CN¥191.5m (up 45% from 3Q 2020). Profit margin: 14% (down from 19% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥17.55, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 86% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.61 per share. Valuation Update With 7 Day Price Move • Aug 26
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥20.82, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 160% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥24.22 per share.